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The following review has been prepared in collaboration with members of the MRC-NIHR Trials 
Methodology Research Partnership​1​. The reviewers named above, and other, unnamed 
discussants of the paper, are all qualified statisticians with experience in clinical trials. Our 
objective is to provide a rapid review of publications, preprints and protocols from clinical trials of 
COVID-19 treatments, independent of journal specific review processes. We aim to provide 
timely, constructive, focused, clear advice aimed at improving both the research outputs under 
review, as well as future studies. Given our collective expertise (clinical trial statistics) our 
reviews focus on the designs of the trials and other statistical content (methods, presentation 
and accuracy of results, inferences). This review reflects the expert opinions of the named 
authors, and does not imply endorsement by the MRC-NIHR Trials Methodology Research 
Partnership, its wider membership, or any other organization.  
 
Here we review ​Remdesivir in adults with severe COVID-19: a randomised, double-blind, 
placebo-controlled, multicentre trial ​by Wang ​et al ​2​, ​which was published in The Lancet, April 
29, 2020.  
 
Overall, this was a well-conducted, well-reported trial, which was faithful to a 
pre-registered, openly available study protocol. Our comments on the paper, detailed 
below, are all minor in nature. The trial ended early, roughly half-way to its planned 
sample size, once successful infection control efforts in the region made it difficult to 
recruit new patients. It is perhaps not surprising then that the study did not demonstrate 
any substantial effects of remdesivir, though the authors correctly noted that the study 
was too small to rule out potentially important effects. Regardless, it will be important for 
investigators and decision makers to take data from this study into account as our 
understanding of COVID-19 treatment grows.   
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Study Summary 
The paper reports a two-arm parallel randomized controlled trial planned in 453 patients 
hospitalized with rt-PCR confirmed COVID-19. The study was conducted in 10 COVID-19 
treatment centers in Wuhan, China, between Feb 6 and March 12, 2020. Patients were 
randomized using a 2:1 allocation ratio to receive either standard-of-care plus intravenous 
remdesivir (200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions) or 
standard-of-care plus placebo. The primary outcome was the time to clinical improvement up to 
day-28 post-randomization, where clinical status was measured on a 6-category ordinal scale, 
ranging from ​no longer hospitalized ​to ​death​, and improvement was then defined as moving 
down two or more categories (towards better outcomes) on this scale. Key secondary outcomes 
were clinical status at days 7, 14, and 28 (using the same ordinal measure); all-cause mortality 
at day-28; the frequency of invasive mechanical ventilation; the durations of oxygen therapy and 
hospital admission; and detection of viral RNA and viral load during the study period.  
 
Recruitment to the study was stopped early (March 12), at the recommendation of the data 
safety and monitoring board, largely due to the success of infection control measures in Wuhan. 
This resulted in 236 patients in the intention-to-treat analysis sample (158:78). This timing also 
coincided with a planned interim analysis that was described in the pre-registered protocol and 
the paper​. ​Overall, the results did not suggest any substantial differences in outcomes between 
the two study arms. The median time to clinical improvement in the remdesivir group was 21 
days (IQR 13-28), vs 23 days (15-28) in the placebo arm (HR 1·23, 95% CI 0.87 to 1.75). 
Mortality at 28 days was also similar between the two groups (a risk difference of 1.1% favoring 
placebo; 95% CI −8.1 to 10.3). The authors reported no other meaningful differences between 
the two groups.  
 
Based on these findings, the authors appropriately concluded that “this dose regimen of 
intravenous remdesivir was adequately tolerated but did not provide significant clinical or 
antiviral effects in seriously ill patients with COVID-19. However, we could not exclude clinically 
meaningful differences and saw numerical reductions in some clinical parameters. Ongoing 
studies with larger sample sizes will continue to inform our understanding of the effect of 
remdesivir on COVID-19.”  
 
We sincerely thank the authors for their contribution to our collective understanding of 
COVID-19, for their commitment to the timely, clear, and complete dissemination of research 
results, and their transparency in pre-registering their full study protocol.   
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Minor points 
 
- Similar to another COVID-19 trial we reviewed​3​, this study used a 6-level ordinal endpoint for 
clinical status, ranging from ​no longer hospitalized ​to ​death​. They then dichotomized this 
outcome, defining improved clinical status as moving down two or more categories (towards 
better outcomes) on this scale. This allowed the investigators to use a time-to-event analysis. In 
our previous review of the study with the same outcome, we commented that the 
dichotomization could lead to reduced power, which is a critique we still think has merit. 
However, in response​4​, one of the statisticians on the previous paper we reviewed (Dr Thomas 
Jaki) made an important point, which was that the time spent utilizing hospital resources is an 
important outcome in the context of COVID-19, and that their dichotomization of the ordinal 
outcome was their approach to dealing with this important issue.  
 
This ordinal outcome was previously proposed for use in influenza trials​5​, seemingly to allow for 
a single, useful endpoint that could be used to accommodate multiple important outcomes 
observed in a patient population at various stages of disease. Its potential use in COVID-19 
trials was noted in early reports from the WHO R&D Blueprint for COVID-19, but they have more 
recently suggested moving to a simpler endpoint​6​; and while a similar ordinal endpoint has been 
included in COVID-19 core outcome sets​7​, the recommendation is to analyze it with ordinal 
models. Our own opinion is that studies should feel free to use multiple outcomes as needed if 
the goal is to understand a treatment’s impact on both patient-focused outcomes, such as 
mortality and disability, where the element of timing is less pertinent, and resource usage 
outcomes, such as time spent in hospital or the ICU, where the element of timing is crucial​8​. 
Importantly, Wang ​et​ ​al​, did exactly that, in addition to the dichotomized ordinal outcome, by 
including secondary outcomes such as mortality at 28 days and time spent on ECMO.  
 
- The randomization was stratified, but the stratifier was not adjusted for in the reported 
analysis, meaning that the standard errors were not calculated correctly. Further, the analysis 
did not take advantage of prognostic covariates measured prior to randomization. Using 
multivariable models to adjust for these covariates would have led to more precise estimates of 
the treatment effects​9​ and more appropriate conditional estimates of effects for non-linear 
models, and thus represents a missed opportunity to learn as much as possible with the data at 
hand.  
 
- Patients were allocated in a 2:1 ratio (remdesivir vs placebo), but this choice wasn’t justified in 
the paper. While there can be reasons for uneven allocation, it comes at a cost to the power and 
precision of the analysis, so it’s important to balance any potential gains against this cost.  
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- The randomisation was well concealed with a central list created using random permuted 
blocks of 30 with a single two-level stratification factor. With this in mind, it was unusual that the 
actual allocation was exactly 2:1, given that there will have been at least one incomplete block. 
 
- The timing for stopping the study early coincided with a planned interim analysis, which was 
noted in the pre-registered protocol. The authors, correctly in our opinion, decided to treat the 
reported analysis as final, rather than interim. This makes sense as there were no prior looks at 
the data, and the decision to stop the study when they did was not made in light of the data, but 
rather the impossibility for patient recruitment.  
 
- The final follow-up was noted as April 10, but the analysis after early stopping was noted as 
taking place on March 29 
 
- The majority of the secondary outcomes were reported as specified, though there were some 
omissions. The registration indicated analysis of clinical status at day 21, as well as days 7, 14 
and 28, while the paper only reported the latter three. Similarly, the duration of ECMO was 
missing in the analysis and in general it is not clear how patients who started to receive 
mechanical ventilation after randomisation were dealt with in the analysis, which seems to 
presume they all were on it at the beginning. ​Time to discharge​ was analysed rather than ​time 
to disease improvement​, as noted in the protocol, which was defined as discharge or a NEWS2 
score ≤ 2, maintained for 24 hours. The text (but not the table) also presented time to 
improvement and time to deterioration based on a change of 1 point on the ordinal outcome, 
which was not prespecified. 
 
- The subgroup analysis appears to have been prespecified, which is a positive, but it wasn’t 
clear why ​days of symptoms​ was categorized, especially given the low power of the study. 
Further, the estimate appears to be based on a within-subgroup analysis, rather than the 
recommended approach of adding an interaction term in a multivariable model. 
 
Open Data 
No.  
Open Analysis Code 
No.  
Pre-registered study design 
Yes. 
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PubPeer 
There may be comments on the PubPeer page for the published version of this paper. 
https://pubpeer.com/publications/9C9A1AA1343F05CB5458B573C3694B 
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CONSORT CHECKLIST 
To support the review, we completed the CONSORT checklist​ 10​ below. Material taken directly 
from the paper (or trial registry) is in ​italics. ​Our additional comments are in ​bold​.  
Title and abstract 
1a Identification as a randomised trial in the title 
Yes 
1b Structured summary of trial design, methods, results, and conclusions. 
Title: Identification of the study as randomised Yes 
Authors: Contact details for the corresponding author Yes 
Trial design: Description of the trial design (eg, parallel, cluster, non-inferiority) No 
Methods  
Participants: Eligibility criteria for participants and the settings where the data were collected Yes 
Interventions: Interventions intended for each group Yes 
Objective: Specific objective or hypothesis No 
Outcome: Clearly defined primary outcome for this report Yes 
Randomisation: How participants were allocated to interventions Yes 
Blinding (masking): Whether or not participants, care givers, and those assessing the outcomes were 
blinded to group assignment 
Yes 
Results  
Numbers randomised: Number of participants randomised to each group Yes 
Recruitment: Trial status Yes 
Numbers analysed: Number of participants analysed in each group Yes 
Outcome: For the primary outcome, a result for each group and the estimated effect size and its precision Yes 
Harms: Important adverse events or side-effects Yes 
Conclusions: General interpretation of the results Yes 
Trial registration: Registration number and name of trial register Yes 
Funding: Source of funding Yes 
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Introduction 
Background and objectives 
2a Scientific background and explanation of rationale 
Yes, see introduction.  
2b Specific objectives or hypotheses 
However, the clinical and antiviral efficacy of remdesivir in COVID-19 remains to be established. 
Here, we report the results of a placebo-controlled randomised trial of remdesivir in patients with 
severe COVID-19. 
Methods 
Trial design 
3a Description of trial design (such as parallel, factorial) including allocation ratio 
This was an investigator-initiated, individually randomised, placebo-controlled, double-blind 
trial… 
 
Eligible patients were randomly assigned (2:1) to either the remdesivir group or the placebo 
group. 
Participants 
4a Eligibility criteria for participants 
Eligible patients were men and non-pregnant women with COVID-19 who were aged at least 18 
years and were RT-PCR positive for SARS-CoV-2, had pneumonia confirmed by chest imaging, 
had oxygen saturation of 94% or lower on room air or a ratio of arterial oxygen partial pressure 
to fractional inspired oxygen of 300 mm Hg or less, and were within 12 days of symptom onset. 
Eligible patients of child-bearing age (men and women) agreed to take effective contraceptive 
measures (including hormonal contraception, barrier methods, or abstinence) during the study 
period and for at least 7 days after the last study drug administration.  
 
Exclusion criteria included pregnancy or breast feeding; hepatic cirrhosis; alanine 
aminotransferase or aspartate aminotransferase more than five times the upper limit of normal; 
known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m​2​) or 
receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis; 
possibility of transfer to a non-study hospital within 72 h; and enrolment into an investigational 
8 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
10.5281/zenodo.3819778 
treatment study for COVID-19 in the 30 days before screening. The use of other treatments, 
including lopinavir–ritonavir, was permitted.  
4b Settings and locations where the data were collected 
The trial was done at ten hospitals in Wuhan, Hubei, China. 
Interventions 
5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
Patients received either intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 
2–10 in single daily infusions) or the same volume of placebo infusions for a total of 10 days 
(both provided by Gilead Sciences, Foster City, CA, USA).  
Outcomes 
6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
Patients were assessed once daily by trained nurses using diary cards that captured data on a 
six-category ordinal scale and safety from day 0 to 28 or death. Other clinical data were 
recorded using the WHO–International Severe Acute Respiratory and Emerging Infections 
Consortium (​ISARIC​) case record form. 
 
The primary clinical endpoint was ​time to clinical improvement within 28 days after 
randomisation​. Clinical improvement was defined as a two-point reduction in patients' admission 
status on a six-point ordinal scale, or live discharge from the hospital, whichever came first. The 
six-point scale was as follows: death=6; hospital admission for extracorporeal membrane 
oxygenation or mechanical ventilation=5; hospital admission for non-invasive ventilation or 
high-flow oxygen therapy=4; hospital admission for oxygen therapy (but not requiring high-flow 
or non-invasive ventilation)=3; hospital admission but not requiring oxygen therapy=2; and 
discharged or having reached discharge criteria (defined as clinical recovery—ie, normalisation 
of pyrexia, respiratory rate <24 breaths per minute, saturation of peripheral oxygen >94% on 
room air, and relief of cough, all maintained for at least 72 h)=1. The six-point scale was 
modified from the seven-point scale used in our previous COVID-19 lopinavir–ritonavir RCT 
by combining the two outpatient strata into one.​ [​paper​] 
 
Time to Clinical Improvement (TTCI) [Censored at Day 28] [ Time Frame: up to 28 days ] 
The primary endpoint is time to clinical improvement (censored at Day 28), defined as the time 
(in days) from randomization of study treatment (remdesivir or placebo) until a decline of two 
categories on a six-category ordinal scale of clinical status (1   discharged; 6   death) or live 
discharge from hospital. 
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Six-category ordinal scale: 
6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC 
therapy; 3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC); 2. 
Hospitalization, not requiring supplemental oxygen; 
1. Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical 
recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief). 
Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; 
HFNC, High-flow nasal cannula. ​[registry] 
 
 
Secondary outcomes were the proportions of patients in each category of the six-point scale at 
day 7, 14, and 28 after randomisation; all-cause mortality at day 28; frequency of invasive 
mechanical ventilation; duration of oxygen therapy; duration of hospital admission; and 
proportion of patients with nosocomial infection. Virological measures included the proportions 
of patients with viral RNA detected and viral RNA load (measured by quantitative RT-PCR). 
Safety outcomes included treatment-emergent adverse events, serious adverse events, and 
premature discontinuations of study drug. ​[​paper​] 
 
● Clinical status [ Time Frame: days 7, 14, 21, and 28 ] 
● Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 
maintained for 24 hours. [ Time Frame: up to 28 days ] 
All cause mortality [ Time Frame: up to 28 days ] 
● Duration (days) of mechanical ventilation [ Time Frame: up to 28 days ] 
● Duration (days) of extracorporeal membrane oxygenation [ Time Frame: up to 28 days ] 
● Duration (days) of supplemental oxygenation [ Time Frame: up to 28 days ] 
● Length of hospital stay (days) [ Time Frame: up to 28 days ] 
● Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens [ 
Time Frame: up to 28 days ] 
● Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract 
specimens as assessed by area under viral load curve. [ Time Frame: up to 28 days ] 
● Frequency of serious adverse drug events [ Time Frame: up to 28 days ] ​[registry] 
 
6b Any changes to trial outcomes after the trial commenced, with reasons 
Sample size 
7a How sample size was determined 
The original design required a total of 325 events across both groups, which would provide 80% 
power under a one-sided type I error of 2·5% if the hazard ratio (HR) comparing remdesivir to 
placebo is 1·4, corresponding to a change in time to clinical improvement of 6 days assuming 
that time to clinical improvement is 21 days on placebo. 
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7b When applicable, explanation of any interim analyses and stopping guidelines 
One interim analysis using triangular boundaries​ ​and a 2:1 allocation ratio between remdesivir 
and placebo had been accounted for in the original design. Assuming an 80% event rate within 
28 days across both groups and a dropout rate of 10% implies that about 453 patients should 
be recruited for this trial (151 on placebo and 302 on remdesivir). The possibility for an interim 
analysis after enrolment of about 240 patients was included in the design if requested by the 
independent data safety and monitoring board. ​[​paper​] 
 
One interim analysis for efficacy and futility will be conducted once half of the total number of 
events required had been observed...An interim analysis is planned for futility and efficacy using 
triangular boundaries. Additionally, sample size may be re-estimated at the interim 
analysis...The primary outcome is time to clinical improvement up to day 28. The total number of 
events required in this study is to be 325 events in total. ​[​protocol​] 
Randomisation 
Sequence generation 
8a Method used to generate the random allocation sequence 
The permuted block (30 patients per block) randomisation sequence, including stratification, 
was prepared by a statistician not involved in the trial using SAS software, version 9.4. ​[​paper​] 
 
The allocation sequence is generated according to computer-generated random numbers. 
[​protocol​] 
8b Type of randomisation; details of any restriction (such as blocking and block size) 
Randomisation was ​stratified ​according to the level of respiratory support as follows: (1) no 
oxygen support or oxygen support with nasal duct or mask; or (2) high-flow oxygen, 
non-invasive ventilation, invasive ventilation, or extracorporeal membrane oxygenation.  
 
The ​permuted block ​(30 patients per block) randomisation sequence, including stratification, 
was prepared by a statistician not involved in the trial using SAS software, version 9.4. ​[​paper​] 
 
Patient randomisation is stratified based on respiratory support methods at the time of 
enrolment: (1) no oxygen support, oxygen support with nasal duct or mask; (2) high-flow 
oxygen, non-invasive ventilation, invasive ventilation/ECMO.​ [​protocol​] 
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Allocation concealment mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
Eligible patients were allocated to receive medication in individually numbered packs, according 
to the sequential order of the randomisation centre (Jin Yin-tan Hospital central pharmacy). 
Envelopes were prepared for emergency unmasking.​ [​paper​] 
 
The allocation sequences are kept in sealed, opaque envelopes. Remdesivir and placebo are 
pre-blinded and stored in a secure area in the pharmacy at a temperature strictly controlled 
according to the protocol. An independent pharmacist is assigned to dispense the study drug in 
water-proof, sealed, opaque bags.​ [​protocol​] 
Implementation 
10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
The allocation sequence was generated by the institutes of Materia Medica, CAMS & PUMC. 
Participants are enrolled by the investigators of each study site. A pharmacist in the central 
pharmacy assigns participants to interventions.​ [​protocol​] 
Blinding 
11a If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
This is a double-blind trial. Trial participants, investigators, care providers, outcome assessors, 
and data analysts are all blinded. Treatment allocation will only be unblinded after database 
lock.​ [​protocol​] 
11b If relevant, description of the similarity of interventions 
Patients received either intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 
2–10 in single daily infusions) or the same volume of placebo infusions for a total of 10 days 
(both provided by Gilead Sciences, Foster City, CA, USA).  
Statistical methods 
12a Statistical methods used to compare groups for primary and secondary outcomes 
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Time to clinical improvement was portrayed by Kaplan-Meier plot and compared with a log-rank 
test. The HR and 95% CI for clinical improvement and HR with 95% CI for clinical deterioration 
were calculated by Cox proportional hazards model.  
 
Other analyses include subgroup analyses for those receiving treatment 10 days or less vs 
more than 10 days after symptom onset, time to clinical deterioration (defined as one category 
increase or death), and for viral RNA load at entry.  
 
The differences in continuous variables between the groups was calculated using 
Hodges-Lehmann estimation.  
 
We present adverse event data on the patients' actual treatment exposure, coded using Medical 
Dictionary for Regulatory Activities.  
 
Statistical analyses were done using SAS software, version 9.4.  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 
Other analyses include subgroup analyses for those receiving treatment 10 days or less vs 
more than 10 days after symptom onset... 
Results 
Participant flow (a diagram is strongly recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
13b For each group, losses and exclusions after randomisation, together with reasons 
 
Between Feb 6, 2020, and March 12, 2020, 255 patients were screened, of whom 237 were 
eligible (​figure 1​). 158 patients were assigned to receive remdesivir and 79 to receive placebo; 
one patient in the placebo group withdrew their previously written informed consent after 
randomisation, so 158 and 78 patients were included in the ITT population.  
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Recruitment 
14a Dates defining the periods of recruitment and follow-up 
Between Feb 6, 2020, and March 12, 2020, 255 patients were screened, of whom 237 were 
eligible.  
14b Why the trial ended or was stopped 
No patients were enrolled after March 12, because of the control of the outbreak in Wuhan and 
on the basis of the termination criteria specified in the protocol, the data safety and monitoring 
board recommended that the study be terminated and data analysed on March 29.  
Baseline data 
15 A table showing baseline demographic and clinical characteristics for each group 
The median age of study patients was 65 years (IQR 56–71); sex distribution was 89 (56%) 
men versus 69 (44%) women in the remdesivir group and 51 (65%) versus 27 (35%) in the 
placebo group (​table 1​). The most common comorbidity was hypertension, followed by diabetes 
and coronary heart disease. Lopinavir–ritonavir was co-administered in 42 (18%) patients at 
baseline. Most patients were in category 3 of the six-point ordinal scale of clinical status at 
baseline. Some imbalances existed at enrolment between the groups, including more patients 
with hypertension, diabetes, or coronary artery disease in the remdesivir group than the placebo 
group. More patients in the control group than in the remdesivir group had been symptomatic for 
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10 days or less at the time of starting remdesivir or placebo treatment, and a higher proportion 
of remdesivir recipients had a respiratory rate of more than 24 breaths per min. No other major 
differences in symptoms, signs, laboratory results, disease severity, or treatments were 
observed between groups at baseline. 
 
Median time from symptom onset to starting study treatment was 10 days (IQR 9–12). No 
important differences were apparent between the groups in other treatments received (including 
lopinavir–ritonavir or corticosteroids;​ ​table 2​). During their hospital stay, 155 (66%) patients 
received corticosteroids, with a median time from symptom onset to corticosteroids therapy of 
8·0 days (6·0–11·0); 91 (39%) patients received corticosteroids before enrolment. 
 
 
Numbers analysed 
16 For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
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The primary efficacy analysis was done on an intention-to-treat (ITT) basis with all randomly 
assigned patients. Time to clinical improvement was assessed after all patients had reached 
day 28; no clinical improvement at day 28 or death before day 28 were considered as right 
censored at day 28.  
Outcomes and estimation 
17a For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval) 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
 
Final follow-up was on April 10, 2020. In the ITT population, the time to clinical improvement in 
the remdesivir group was not significantly different to that of the control group (median 21·0 
days [IQR 13·0–28·0] in the remdesivir group vs 23·0 days [15·0–28·0]; HR 1·23 [95% CI 
0·87–1·75]; 
 
28-day mortality was similar between the two groups (22 [14%] died in the remdesivir group vs 
10 (13%) in the placebo group; difference 1·1% [95% CI −8·1 to 10·3]). 
 
Clinical improvement rates at days 14 and day 28 were also not significantly different between 
the groups, but numerically higher in the remdesivir group than the placebo group.  
 
For patients assigned to the remdesivir group, duration of invasive mechanical ventilation was 
not significantly different, but numerically shorter than in those assigned to the control group; 
however, the number of patients with invasive mechanical ventilation was small.  
 
No significant differences were observed between the two groups in length of oxygen support, 
hospital length of stay, days from randomisation to discharge, days from randomisation to death 
and distribution of six-category scale at day 7, day 14, and day 28 (​table 3​;​ ​appendix p 9​). 
 
Of 236 patients (158 in the remdesivir group and 78 in the placebo group) who were RT-PCR 
positive at enrolment, 37 (19%) of the 196 with data available had undetectable viral RNA on 
the nasopharyngeal and oropharyngeal swab taken at baseline. The mean baseline viral load of 
nasopharyngeal and oropharyngeal swabs was 4·7 log​10​ copies per mL (SE 0·3) in the 
remdesivir group and 4·7 log​10​ copies per mL (0·4) in the control group (​table 1​). Viral load 
decreased over time similarly in both groups (​figure 3A​).  
 
The cumulative rate of undetectable viral RNA of nasopharyngeal and oropharyngeal swabs by 
day 28 was 153 (78%) of 196 patients, and the negative proportion was similar among patients 
receiving remdesivir and those receiving placebo (​appendix p 4​). 
16 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
10.5281/zenodo.3819778 
 
Ancillary analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
 
Results for time to clinical improvement were similar in the per-protocol population (median 21·0 
days [IQR 13·0–28·0] in the remdesivir group vs 23·0 days [15·0–28·0] in the placebo group HR 
1·27 [95% CI 0·89–1·80];​ ​appendix pp 2–3, 5​).  
 
Although not statistically significant, in patients receiving remdesivir or placebo within 10 days of 
symptom onset in the ITT population, those receiving remdesivir had a numerically faster time to 
clinical improvement than those receiving placebo (median 18·0 days [IQR 12·0–28·0] vs 23·0 
days [15·0–28·0]; HR 1·52 [0·95–2·43];​ ​appendix p 6​).  
 
If clinical improvement was defined as a one, instead of two, category decline, the HR was 1·34 
with a 95% CI of 0·96–1·86 (​appendix p 7​).  
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For time to clinical deterioration, defined as a one-category increase or death, the HR was 0·95 
with a 95% CI of 0·55–1·64 (​appendix p 8​). 
 
In patients with use of remdesivir within 10 days after symptom onset, 28-day mortality was not 
significantly different between the groups, although numerically higher in the placebo group; by 
contrast, in the group of patients with late use, remdesivir patients had numerically higher 
28-day mortality, although there was no significant difference.  
 
No differences in viral load were observed when stratified by interval from symptom onset to 
start of study treatment (​appendix p 10​). In the subset of patients from whom expectorated 
sputa could be obtained (103 patients), the mean viral RNA load at enrolment was nearly 1-log 
higher in the remdesivir group than the placebo group at enrolment (​figure 3B​). When adjusted 
for baseline sputum viral load at enrolment, the remdesivir group showed no significant 
difference at day 5 from placebo, but a slightly more rapid decline in load (p=0·0672). 
Harms 
19 All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms) 
The safety assessment included daily monitoring for adverse events, clinical laboratory testing 
(days 1, 3, 7, and 10), 12-lead electrocardiogram (days 1 and 14), and daily vital signs 
measurements.  
 
We present adverse event data on the patients' actual treatment exposure, coded using Medical 
Dictionary for Regulatory Activities.  
 
Adverse events were reported in 102 (66%) of 155 patients in the remdesivir group and 50 
(64%) of 78 in the control group (​table 4​). The most common adverse events in the remdesivir 
group were constipation, hypoalbuminaemia, hypokalaemia, anaemia, thrombocytopenia, and 
increased total bilirubin; and in the placebo group, the most common were hypoalbuminaemia, 
constipation, anaemia, hypokalaemia, increased aspartate aminotransferase, increased blood 
lipids, and increased total bilirubin. 28 (18%) serious adverse events were reported in the 
remdesivir group and 20 (26%) were reported in the control group. More patients in the 
remdesivir group than the placebo group discontinued the study drug because of adverse 
events or serious adverse events (18 [12%] in the remdesivir group vs four [5%] in the placebo 
group), among whom seven (5%) were due to respiratory failure or acute respiratory distress 
syndrome in the remdesivir group. All deaths during the observation period were judged by the 
site investigators to be unrelated to the intervention). 
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Discussion 
Limitations 
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
 
Limitations of our study include insufficient power to detect assumed differences in clinical 
outcomes, initiation of treatment quite late in COVID-19, and the absence of data on infectious 
virus recovery or on possible emergence of reduced susceptibility to remdesivir. Of note, in 
non-human primates, the inhibitory effects of remdesivir on infectious SARS-CoV-2 recovery in 
bronchoalveolar lavages were much greater than in controls, but viral RNA detection in upper 
and lower respiratory tract specimens were not consistently decreased versus controls. 
Coronaviruses partially resistant to inhibition by remdesivir (about six-times increased EC​50​) 
have been obtained after serial in vitro passage, but these viruses remain susceptible to higher 
remdesivir concentrations and show impaired fitness. The frequent use of corticosteroids in our 
patient group might have promoted viral replication, as observed in SARS and MERS, although 
these studies only reported prolongation of the detection of viral RNA, not infectious virus. 
Furthermore, we have no answer to whether longer treatment course and higher dose of 
remdesivir would be beneficial in patients with severe COVID-19. 
Generalisability 
21 Generalisability (external validity, applicability) of the trial findings 
Interpretation 
22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
 
In summary, we found that this dose regimen of intravenous remdesivir was adequately 
tolerated but did not provide significant clinical or antiviral effects in seriously ill patients with 
COVID-19. However, we could not exclude clinically meaningful differences and saw numerical 
reductions in some clinical parameters. Ongoing studies with larger sample sizes will continue to 
inform our understanding of the effect of remdesivir on COVID-19. Furthermore, strategies to 
enhance the antiviral potency of remdesivir (eg, higher-dose regimens, combination with other 
antivirals, or SARS-CoV-2 neutralising antibodies) and to mitigate immunopathological host 
responses contributing to COVID-19 severity (eg, inhibitors of IL-6, IL-1, or TNFα) require 
rigorous study in patients with severe COVID-19. 
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Other information 
Registration 
23 Registration number and name of trial registry 
https://clinicaltrials.gov/ct2/show/NCT04257656 
Protocol 
24 Where the full trial protocol can be accessed, if available 
https://www.researchsquare.com/article/rs-14618/v1 
Funding 
25 Sources of funding and other support (such as supply of drugs), role of funders 
Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key 
Research and Development Program of China, the Beijing Science and Technology Project. 
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